• About
  • Subscribe
  • Advertise
  • Contact
Tuesday, May 20, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Local

Health funds not hiding ‘pot of gold’

by Myles Hume
September 9, 2020
in Local, News
Reading Time: 4 mins read
A A
Thousands of Australians have dropped their private insurance cover during the COVID-19 pandemic.

Thousands of Australians have dropped their private insurance cover during the COVID-19 pandemic.

Share on FacebookShare on Twitter

The private health insurance sector has repeated its claim that health funds are not profiting from a reduction of eyecare and other health services enforced during the initial peak of the COVID-19 pandemic.

Dr Rachel David, CEO of peak industry body Private Healthcare Australia (PHA), says the sector is “not hiding a pot of gold”, following reports that insurers initially saved $515 million on extras services such as optical and $500 million on cancelled elective surgery during the six-week lockdown between March and May.

Rachel David.

David said so far more than half a billion dollars of pandemic-related savings have already been returned to customers, with the remaining funds needed for catch-up procedures among other costs.

Health funds, she said, are governed by strict regulatory and capital requirements and the Australian Prudential Regulation Authority (APRA) has made it clear the sector must retain enough capital to fund an elective surgery backlog and additional private healthcare.

“Health funds made some savings over the six-week period in which elective surgeries were cancelled and some allied health providers were closed,” David said.

“Health funds have repeatedly and publicly said they will not profit from the COVID-19 restrictions. Elective surgeries were not cancelled, they were postponed. Members who needed joint replacements, cataracts and endometriosis surgery still do post-COVID. Dental and allied health appointments have now returned to normal levels.”

Some funds have provided members with cash backs, rollover of services to the next calendar year.

In July, Insight reported that thousands of people dropped their private health cover in the first quarter of 2020 as they were unable to access services they were paying for. PHA says optical services resumed back to normal levels by the end of June, but the latest figures from the June quarter show that thousands of additional customers have dropped their cover.

The June data also revealed the net margin of Australia’s health funds fell to a low of 2.8%. This compares with 4.9% in the twelve months to June 2019 and represents a 42% decline in profitability.  David said this puts to bed suggestions health funds made “windfall gains”.

According to David, the $500 million returned to members came in the form of postponing the April 1 premium increase for six months; financial hardship provisions for people who were unemployed or under- employed due to COVID-19; and funding of telehealth services for psychology, physiotherapy and more.

“Some funds have also provided members with cash backs, rollover of services to the next calendar year and cancelled the October 1 premium increase. If the independent regulator’s claims data … shows more savings need to be returned to members, health funds will do so,” David said.

She added that the COVID-19 situation had not stopped health inflation rising at levels above general inflation and although health funds did not want to increase premiums, it would be necessary to ensure they remain financially viable and meet statutory prudential requirements.

‘Cancel the price hike’

Australian consumer group CHOICE says all private health funds should cancel their upcoming October price rises.

Dean Price.

“Reports that private health funds have made mega profits out of COVID-19 show they must provide some relief to Australians,” CHOICE health campaigner Mr Dean Price said.

“Funds are charging full price while not delivering the full range of healthcare services. They can’t get away with doing the bare minimum while raking in these profits. The October price rises must be scrapped for the good of the community.”

Price said the June quarter APRA figures show a dramatic drop in the number of surgeries and treatments being covered by private health insurance during COVID-19.

“Privately insured hospital services have gone down 19% compared to the same quarter last year and extras have gone down 30% compared to the same quarter last year. Private health insurers are making massive savings this year as fewer people claim on insurance. That’s why private health insurers can’t justify putting people’s premiums up on 1 October 2020.”

More reading

Health funds lay out pandemic blueprint amid declining membership

Tags: APRAAustralian Prudential Regulation AuthorityCHOICE health campaigner Mr Dean PriceCOVID-19health fundprivate health insuranceRachel Davidsavings

Related Posts

geographic atrophy treatments

Exploring geographic atrophy: Managing patients and progress in treatments

by Rob Mitchell
May 20, 2025

At the completion of this article, the reader should be able to: Manage patient expectations and adherence to treatment, in...

The company has developed an “age-related myopia management lens solution”. Image: ZEISS.

New ZEISS MyoCare myopia lens data

by Staff Writer
May 20, 2025

The latest one-year and two-year results from the ongoing multi-centre trials of ZEISS MyoCare lenses consistently demonstrate the slowing of...

A patient’s right to access may include being provided with a copy of their records, inspecting them, and providing a copy to an authorised third party. Image: pandpstock001/Shutterstock.com.

Can I have a full copy of my medical records?

by Staff Writer
May 19, 2025

Blanket requests to obtain medical records can blindside and overwhelm an unsuspecting practice, so how should they be handled? Georgie...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited